Despite promising clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial difficulty from pharmacy benefit managers. The companies are https://jayzcey862822.blogofoto.com/73515983/copyright-s-drug-faces-is-encountering-pbm-hurdles-the-review-of-reimbursement-disputes